By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news originating from Andhra Pradesh, India, by NewsRx correspondents, research stated, "Chaperone protein Hsp90 maintains functional integrity and maturation of a large number of cellular proteins including transcription factors, kinases, etc. It is often over-expressed in cancer cells for simultaneous maintenance of many non-regulated and/or genetically mutated proteins."
Our news journalists obtained a quote from the research from the Council of Scientific and Industrial Research (CSIR), "Small molecule-based regimens inhibiting over-expressing Hsp90 in cancer cells often plagued with improper targeting leading to non-specific toxicity. Recently using a glucocorticoid receptor (GR)-targeted cationic lipoplex, we observed cancer cell-specific GR-transactivation and transgene expression by utilizing an unprecedentedly compromised chaperone-activity of cancer cell-associated Hsp90. In normal cells, GR is expressed ubiquitously and is highly regulated and chaperoned by Hsp90. This does not allow cancer cell-alike GR-mediated transgene expression. As a novel anticancer strategy, we showed that compromising Hsp90 in cancer cells can be utilized to selectively deplete its own level by delivering a specially designed artificial miRNA-plasmid against Hsp90 (amiR-Hsp90). Practically, GR-mediated delivery of amiR-Hsp90 plasmid in tumor-bearing mice, depleted Hsp90, critically down-regulated levels of Akt, VEGFR2 and other Hsp90-client proteins but up-regulated wild-type p53 in tumor. These enforced apoptosis in angiogenic vessels and in tumor mass and significantly shrunk tumor-volume."
According to the news editors, the research concluded: "The present study describes gene therapy strategy against Hsp90 using a new GR-targeted liposome-amiR-Hsp90 lipoplex formulation for treating cancer."
For more information on this research see: Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials, 2013;34(28):6804-6817. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news correspondents report that additional information may be obtained from S.K. Pore, Center Cellular & Mol Biol, CSIR, Hyderabad 500007, Andhra Pradesh, India. Additional authors for this research include A. Choudhary, B. Rathore, A. Ganguly, P. Sujitha, C.G. Kumar, S.B. Agawane, J.M. Kumar, V. Scaria, B. Pillai and R. Banerjee (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, India, Genetics, Oncology, Peptides, Proteins, Liposomes, Amino Acids, Andhra Pradesh, Bioengineering, Cancer Gene Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC